Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07141329 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

StatusRecruiting
PhasePhase 2
Started2025-07-30
View on ClinicalTrials.gov ↗

Amendment history

2025-10-06
Study Identification, Study Status, Study Description, Study Design v1
PhasePhase 3→Phase 2
Study description-40 characters
This is a Phase 32b, multicenter, open-label extension, one-year, safety, toler [...] completed an applicable double-blind SPN-817 clinical study (including a Phase 2 double-blind study). This study will include a double-blind Dose Titration/Brid [...]
2025-08-19
Original filing
This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.
Trial Details
NCT Number NCT07141329
Lead Sponsor Supernus Pharmaceuticals, Inc.
Conditions Focal Onset Seizures
Enrollment 100 participants
Start Date 2025-07-30
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-10